stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Net income
Harmony Biosciences Holdings, Inc.'s net income for fiscal 2025 was $158.7M, up 9.07% from $145.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $178.6M. Over the past ten years it has ranged from −$152.0M (fiscal 2019) to $181.5M (fiscal 2022); the current reading is higher than 89% of that period. Harmony Biosciences Holdings, Inc. ranks 26th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $158.7M | 9.07% |
| FY2024 | $145.5M | 12.91% |
| FY2023 | $128.9M | (28.99%) |
| FY2022 | $181.5M | 424.52% |
| FY2021 | $34.6M | — |
| FY2020 | −$36.9M | — |
| FY2019 | −$152.0M | — |
| FY2018 | −$39.9M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $48.2M | (36.11%) |
| Jun 2026 | $75.4M | 132.18% |
| Mar 2026 | $32.5M | 44.48% |
| Dec 2025 | $22.5M | (55.79%) |
| 26 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. | $178.6M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $16.3M |
| TRVI Trevi Therapeutics, Inc. compare | −$51.1M |
| FTRE Fortrea Holdings Inc. compare | −$68.7M |
| SRPT Sarepta Therapeutics, Inc. compare | −$114.6M |
| MESO Mesoblast Limited compare | −$128.6M |
| MAZE Maze Therapeutics, Inc. compare | −$133.6M |
| VIR Vir Biotechnology, Inc. compare | −$184.8M |
| REPL Replimune Group, Inc. compare | −$271.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item